Clinical Trial is underway
This study is currently recruiting participants.
For details see ClinicalTrials.gov
It has been verified in July 2016 by AIDS Clinical Trials Group
The Sponsor: AIDS Clinical Trials Group
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID) Exegi Pharma, LLC
The purpose of the study is to evaluate whether the probiotic Visbiome Extra Strength reduces inflammation in HIV-infected men and women when compared to a placebo (inactive medication like a dummy pill).
The study will evaluate whether taking Visbiome Extra Strength by mouth for 24 weeks is safe and well-tolerated for HIV-infected persons on antiretroviral therapy (ART).
Probiotics are germs such as yeast or bacteria that are found in food and supplements that are used to improve the health of the digestive system. Many people refer to probiotics as "helpful bacteria." These bacteria live in the body and help the body work normally. In some medical conditions, including HIV infection, helpful bacteria are replaced with bacteria that can change the normal intestinal function and increase inflammation.
The investigators will test whether giving a probiotic can restore normal intestinal function and decrease inflammation.